AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 12 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced that it has launched Contour SE in the U.S. to treat hypervascular tumors and arteriovenous malformations (AVMs).
Contour SE is made of polyvinyl acetate (PVA), a material that has been used extensively in embolization procedures for more than 20 years. Contour SE is designed to shrink and destroy hypervascular tumors and AVMs by blocking the blood supply feeding them.
The company also announced that it has received FDA authorization to perform a clinical trial (IDE) to evaluate uterine artery embolization (UAE) for the treatment of uterine fibroids (benign, smooth muscle tumors) using Contour SE. The clinical trial is the third arm of an earlier trial designed to demonstrate that UAE is an effective alternative to surgery for women suffering from symptomatic uterine fibroids. The investigational arm, comprising patients receiving UAE procedures using standard PVA particles, and the myomectomy surgical control arm have now been completed. The third arm is currently enrolling patients.
UAE is being studied as a possible alternative to myomectomy and hysterectomy, the standard surgical therapies for uterine fibroids. UAE is a less-invasive procedure that blocks blood flow to the vessels feeding the fibroid. By depriving the fibroid of its blood supply, UAE may reduce the symptoms associated with uterine fibroids.
"Contour SE spherical embolic provides excellent flow characteristics and effective embolization as compared to other spherical embolic agents in our animal model," said Gary ...
Source: HighBeam Research, Contour SE designed to shrink, destroy uterine fibroids.